Rhumbline Advisers Trevena Inc Transaction History

Rhumbline Advisers

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.2 - $0.5 $28,836 - $72,090	-144,181 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$0.41 - $0.63 $4,008 - $6,159	-9,777 Reduced 6.35%	144,181 $79,000
Q4 2021 Feb 10, 2022	SELL	$0.57 - $1.29 $2,386 - $5,399	-4,186 Reduced 2.65%	153,958 $90,000
Q3 2021 Nov 12, 2021	BUY	$1.11 - $1.7 $5,392 - $8,258	4,858 Added 3.17%	158,144 $195,000
Q2 2021 Aug 05, 2021	BUY	$1.46 - $2.25 $223,797 - $344,893	153,286 New	153,286 $259,000
Q2 2018 Aug 06, 2018	SELL	$1.44 - $2.24 $78,811 - $122,595	-54,730 Closed	0 $0
Q1 2018 May 02, 2018	SELL	$1.51 - $2.06 $2,265 - $3,090	-1,500 Reduced 2.67%	54,730 $90,000
Q4 2017 Feb 09, 2018	SELL	$1.4 - $2.6 $12,741 - $23,662	-9,101 Reduced 13.93%	56,230 $90,000
Q3 2017 Nov 06, 2017	BUY	$2.22 - $2.79 $145,034 - $182,273	65,331	65,331 $167,000

Ticker TRVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 173,680,992
Market Cap $273M
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.